| Literature DB >> 34043935 |
Fatemeh Heidary Jamebozorgi1,2, Morteza Yousefzadi1,3, Omidreza Firuzi2, Melika Nazemi4, Somayeh Zare2, Jima N Chandran5, Bernd Schneider5, Ian T Baldwin6, Amir Reza Jassbi2.
Abstract
CONTEXT: Ircinia mutans Wilson (Irciniidae) is a sponge with antimicrobial and cytotoxic constituents.Entities:
Keywords: Furanosesquiterpenes; cholesterol; ergosterol; marine sponge; stigmasterol; γ-sitosterol
Mesh:
Substances:
Year: 2021 PMID: 34043935 PMCID: PMC8168774 DOI: 10.1080/13880209.2021.1920620
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.503
Figure 1.Structures of furodysin (1), furodysinin (2), and furoircin (3) isolated from Ircinia mutans.
Figure 2.Structures of steroids identified from Ircinia mutans.
Figure 3.HPLC chromatograms of the subfraction FS6-10- F25-29 (steroids fraction) isolated from I. mutans (summer sample).
Figure 4.GC-MS chromatograms of FH2-FH5 of the HPLC semi-purified compounds 4–13 from FS6-10- F25-29 (steroids fraction) isolated from I. mutans (summer sample).
1H NMR (500 MHz) and 13C NMR (125 MHz) data of furoircin (3) in CDCl3.
| position | δH ( | 1H-1H COSY | δC (HSQC) | HMBC |
|---|---|---|---|---|
| 1 | 7.34 brt ( | H-2 | 142.46 | C-2, C-3, C-4 |
| 2 | 6.24 brd ( | – | 111.49 | C-1, C-3, C-4, C-12 |
| 3 | – | – | 123.82 | – |
| 4 | 7.17 brs | H-2, H-11 | 139.40 | C-1, C-2, C-3, C-11, C-12 |
| 5 | – | – | 147.63 | – |
| 6 | 2.24 ddd ( | H-7 | 43.80 | C-5, C-7, C-8, C-11, C-12, C-13 |
| 7 | 1.68 m | – | 22.50 | C-5, C-6, C-8, C-9, C-11 |
| 8 | 2.00 m | H-7 | 30.78 | C-6, C-7, C-9, C-10 |
| 9 | – | – | 133.85 | – |
| 10 | 5.39 brdd ( | H-11, H-12′ | 124.94 | C-6, C-8, C-11, C-15 |
| 11 | 2.41 m | H-12′ | 36.77 | C-2, C-4, C-9, C-10, C-12, C-15 |
| 12 | 2.38 dd ( | – | 25.97 | C-2, C-3, C-4, C-6, C-11 |
| 12′ | 2.07 ddd ( | – | 25.97 | C-2, C-3, C-4, C-6, C-11 |
| 13 | 4.87 brs | H-14 | 110.14 | C-5, C-6, C-11(w*), C-14 |
| 13′ | 4.72 brs | H-14, H-6 | 110.14 | C-5, C-6, C-11(w), C-14 |
| 14 | 1.77 s | – | 22.81 | C-5, C-6, C-13 |
| 15 | 1.63 s | – | 23.55 | C-8, C-9, C-10, C-11, C-14 |
*Weak cross peak.
Sterol composition of I. mutans detected by GC-MS.
| Compound | Retention time (min) | Kovats retention index (KI) Column type (HP-5 MS) | Kovats retention index standard (Colum stationary type) | Base peak ( | Molecular weight | Reference for identification |
|---|---|---|---|---|---|---|
| cholesta-5, 22-dien-3β-ol ( | 6.18 | 3087 | 3070 (active phase: methyl Silicone*) | 55 | 384 | webbook.nist.gov |
| cholest-5-en-3β-ol (cholesterol) ( | 6.67 | 3121 | 3192 (active phase: DB-5*) | 43 | 386 | Pherobase.com |
| cholesta-5, 7-dien-3β-ol ( | 7.27 | 3158 | 3160 (active phase: methyl Silicone *) | 351 | 384 | webbook.nist.gov |
| ergosta-5, 7, 22-trien-3β-ol (ergosterol) ( | 8.01 | 3204 | 3152 (active phase: DB-5*) | 363 | 396 | webbook.nist.gov |
| ergosta-5, 24-dien-3β-ol (24-methyl-desmosterol) ( | 8.22 | 3214 | 3230 (active phase: OV-1*) | 314 | 398 | webbook.nist.gov |
| ergost-5-en-3β-ol (campesterol) ( | 8.26 | 3216 | 3131 (active phase: HP-5 MS*) | 43 | 400 | webbook.nist.gov |
| stigmasta-5,22-dien-3β-ol (stigmasterol) ( | 8.97 | 3252 | 3248 (active phase: VF-5MS*) | 412 | 412 | webbook.nist.gov |
| γ-ergostenol (fungisterol) ( | 9.24 | 3265 | 3220 (active phase: Methyl Silicone*) | 400 | 400 | webbook.nist.gov |
| 5α-stigmasta-7,22-dien-3β-ol (chondrillasterol) ( | 9.69 | 3288 | 3295 (active phase: DB-5MS*) | 271 | 412 | webbook.nist.gov |
| γ-sitosterol (clionasterol) ( | 10.13 | 3308 | 3351 (active phase: HP-5 MS*) | 43 | 414 | webbook.nist.gov |
*Column type: VF-5MS; DB-5; HP-5 MS: 5% phenylmethyl polysiloxane, OV-1, DB1 = 100% methylsiloxane
Sterol composition of the HPLC Purified fractions from FS6-10- F25-29, characterised by GC-MS.
| Fraction | Compounds |
|---|---|
| FH2 | Cholesta-5, 22-dien-3β-ol ( |
| Cholesta-5, 7-dien-3β-ol ( | |
| Ergosta-5, 7, 22-trien-3β-ol (ergosterol) ( | |
| Ergosta-5, 24-dien-3β-ol (24-methyldesmosterol) ( | |
| FH3 | Cholest-5-en-3β-ol (cholesterol) ( |
| FH4 | Cholest-5-en-3β-ol (cholesterol) ( |
| Ergost-5-en-3β-ol (campesterol) ( | |
| Stigmasta-5,22-dien-3β-ol (stigmasterol) ( | |
| γ-Ergostenol (fungisterol) ( | |
| 5α-Stigmasta-7,22-dien-3β-ol (chondrillasterol) ( | |
| FH5 | γ-Sitosterol (Clionasterol) ( |
*Area percentage (%) of the detected compounds using GC-MS.
Figure 5.Cytotoxic activity of compounds isolated from I. mutans collected in winter (A) and summer (B) against three human cancer cell lines. Values are presented as mean ± S.E.M. of 3–5 experiments. *Compound 1w was not active against MOLT-4 and MCF-7 cell lines; IC50 > 100 µg/mL. **Compounds 4–13 were not tested against MCF-7 and HT-29 cell lines.
Figure 6.Cytotoxic activity of RP4-HPLC purified steroids isolated from I. mutans (summer sample) against human lymphoblastic leukaemia cell line. Values are presented as mean ± S.E.M. of 3-5 experiments. FH2: Compounds: 5, 6, 7 and 8, FH3: compound 4, FH4: compounds 4, 9, 10, 11 and 12; FH5: compound 13. Based on statistical analysis, cytotoxic activity of FH2 has significant difference with other fractions (p < 0.05) while FH4 and FH5 were not significantly different compared to that of cisplatin as a positive control (p > 0.05).